Fenchone Ameliorates Constipation-Predominant Irritable Bowel Syndrome via Modulation of SCF/c-Kit Pathway and Gut Microbiota
Journal of Microbiology and Biotechnology · 2024
DOI: 10.4014/jmb.2308.08011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, 2024. Verfasst von Li Cui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, P.R. China. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome, Camphanes, Norbornanes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial TCM Science and Technology Development Plan Project, Social Development Project of Jiangsu Province.
Abstract (Originalsprache)
In this study we sought to elucidate the therapeutic effects of fenchone on constipation-predominant irritable bowel syndrome (IBS-C) and the underlying mechanisms. An IBS-C model was established in rats by administration of ice water by gavage for 14 days. Fenchone increased the reduced body weight, number of fecal pellets, fecal moisture, and intestinal transit rate, and decreased the enhanced visceral hypersensitivity in the rat model of IBS-C. In addition, fenchone increased the serum content of excitatory neurotransmitters and decreased the serum content of inhibitory neurotransmitters in the IBS-C rat model. Meanwhile, western blot and immunofluorescence experiments indicated that fenchone increased the expressions of SCF and c-Kit. Furthermore, compared with the IBS-C model group, fenchone increased the relative abundance of Lactobacillus, Blautia, Allobaculum, Subdoligranulum, and Ruminococcaceae_UCG-008, and reduced the relative abundance of Bacteroides, Enterococcus, Alistipes, and Escherichia-Shigella on the genus level. Overall, fenchone ameliorates IBS-C via modulation of the SCF/c-Kit pathway and gut microbiota, and could therefore serve as a novel drug candidate against IBS-C.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, P.R. China.
- Digestive Department, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing 211200, Jiangsu, P.R. China.
- Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210016, P.R. China.
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial TCM Science and Technology Development Plan Project
- Social Development Project of Jiangsu Province
- National Administration of Traditional Chinese Medicine
Zitieren
APA
Cui, L., Zhang, B., Zou, S., Liu, J., Wang, P., Li, H., & Zhang, Z. (2024). Fenchone Ameliorates Constipation-Predominant Irritable Bowel Syndrome via Modulation of SCF/c-Kit Pathway and Gut Microbiota. Journal of Microbiology and Biotechnology. https://doi.org/10.4014/jmb.2308.08011
Vancouver
Cui L, Zhang B, Zou S, Liu J, Wang P, Li H, et al. Fenchone Ameliorates Constipation-Predominant Irritable Bowel Syndrome via Modulation of SCF/c-Kit Pathway and Gut Microbiota. Journal of Microbiology and Biotechnology. 2024. doi:10.4014/jmb.2308.08011
BibTeX
@article{Cui2024,
author = {Cui, Li and Zhang, Bin and Zou, Shuting and Liu, Jing and Wang, Pingrong and Li, Hui and Zhang, Zhenhai},
title = {Fenchone Ameliorates Constipation-Predominant Irritable Bowel Syndrome via Modulation of SCF/c-Kit Pathway and Gut Microbiota},
journal = {Journal of Microbiology and Biotechnology},
year = {2024},
doi = {10.4014/jmb.2308.08011}
}
EUVIMED